{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=197364&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&hansardHeading=Erenumab", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=197364&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&hansardHeading=Erenumab", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=197364&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&_metadata=all&hansardHeading=Erenumab", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=197364&_page=0&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&hansardHeading=Erenumab", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=197364&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&hansardHeading=Erenumab", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=197364&max-ddpModified.=2018-11-30T11%3A37%3A02.099Z&min-AnswerDate=2018-11-26&hansardHeading=Erenumab", "items" : [{"_about" : "http://data.parliament.uk/resources/1017183", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1017183/answer", "answerText" : {"_value" : "
The National Institute of Health and Care Excellence (NICE) is currently developing Technology appraisal guidance on the use of erenumab for preventing migraines. NHS commissioners are legally required to fund drugs and treatments recommended by NICE\u2019s technology appraisal programme. In the absence of positive guidance from NICE, it is for commissioners to make decisions on whether to fund this treatment based on an assessment of the available evidence.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-12-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-12-07T13:07:25.02Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Erenumab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the NHS has to make erenumab available to people with migraines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "197364"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }